OpenEvidence Raises $250M for Drug Development Pivot

In a significant strategic shift, AI-driven healthcare intelligence firm OpenEvidence has reportedly secured $250 million in new funding. This substantial capital infusion, detailed in a Forbes report, signals the company's ambitious pivot from its established role in clinical AI search towards pioneering its own drug development initiatives, particularly in the rare cancer space. This marks the company's fifth funding round, with a reported valuation of $15 billion, a 25% increase from its January Series D round.

The funding was reportedly led by Byers Capital, the family office of Blake Byers, and prominent venture capital firm Andreessen Horowitz. This latest financing follows a rapid ascent for OpenEvidence, which has seen its valuation climb from $3.5 billion in July 2025 to $12 billion just six months ago. The company's CEO, Daniel Nadler, a former Kensho founder acquired by S&P Global, indicated that the first internally developed cancer drug candidate is slated for clinical trials before the end of the year, with an additional three to five candidates planned for the following year.

OpenEvidence's new direction leverages its extensive physician network, aiming to identify and recruit patients for rare disease trials—a segment often overlooked by larger pharmaceutical giants. This strategy is complemented by a new partnership with Memorial Sloan Kettering (MSK). The collaboration involves integrating OpenEvidence's platform into MSK's Epic electronic health record system and, conversely, bringing MSK's highly regarded OncoKB precision oncology database to OpenEvidence's broader physician user base. OncoKB's unique status as an FDA-recognized somatic cancer variant knowledge base adds significant credibility to this venture.

Further underscoring its advanced AI capabilities, OpenEvidence recently unveiled its Darwin model, which achieved a perfect score on the MedQA medical AI benchmark. This sophisticated model, with expertise in virology, immunology, and genetics, is being selectively deployed to institutional partners, including the National Organization for Rare Disorders, aligning perfectly with the company's drug development ambitions. This move positions OpenEvidence at the intersection of AI-powered diagnostics and therapeutic innovation.

The competitive environment for AI in healthcare is intensifying. Rivals like Doximity have reported substantial user growth for their AI scribe tools, while Abridge, backed by Eli Lilly, is expanding into clinical trial recruitment. Big Tech players are also making inroads, with Anthropic launching Claude for Healthcare and OpenAI developing ChatGPT Health. OpenEvidence's strategic pivot into drug development appears to be a proactive response to these pressures, seeking a differentiated path beyond traditional clinical search and documentation solutions.

While the company has not issued a formal press release for this funding round, its quiet execution and ambitious pivot suggest a calculated strategy. Industry observers note that while the reported valuation is a step up, it falls short of earlier reported aspirations for a $20 billion valuation. Nevertheless, the company's focus on rare diseases and its unique data assets provide a compelling narrative for its future growth and impact on pharmaceutical innovation.